Bellicum Pharmaceuticals Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Bellicum Pharmaceuticals prevailing Real Value cannot be determined due to lack of data. The current price of Bellicum Pharmaceuticals is $0.0. Our model approximates the value of Bellicum Pharmaceuticals from analyzing the firm fundamentals such as Shares Outstanding of 9.5 M, operating margin of (19.69) %, and Return On Equity of -1.06 as well as examining its technical indicators and probability of bankruptcy.
Bellicum Pharmaceuticals Total Value Analysis
Bellicum Pharmaceuticals is currently forecasted to have valuation of (38.62 M) with market capitalization of 3.52 M, debt of 58 K, and cash on hands of 33.17 M. The negative valuation of Bellicum Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Bellicum Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(38.62 M) | 3.52 M | 58 K | 33.17 M |
Bellicum Pharmaceuticals Investor Information
About 29.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bellicum Pharmaceuticals recorded a loss per share of 1.57. The entity last dividend was issued on the 6th of February 2020. The firm had 1:10 split on the 6th of February 2020. Based on the key indicators related to Bellicum Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Bellicum Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Bellicum Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bellicum Pharmaceuticals has an asset utilization ratio of 6.3 percent. This suggests that the Company is making $0.063 for each dollar of assets. An increasing asset utilization means that Bellicum Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Bellicum Pharmaceuticals Ownership Allocation
Bellicum Pharmaceuticals shows 4.19 percent of its outstanding shares held by insiders and 29.31 percent owned by other corporate entities.Bellicum Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 1.5 M. Net Loss for the year was (24.97 M) with loss before overhead, payroll, taxes, and interest of (17.38 M).Bellicum Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Bellicum Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 30.8 M | |
| Quarterly Earnings Growth Y O Y | -0.933 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |